Centene Q2 Results Lift Profit Outlook
Centene Q2 results raised 2026 profit guidance on lower medical costs and stronger Medicare, Medicaid and Marketplace lines, tightening EPS expectations.
KEY TAKEAWAYS
- Centene reported Q2 adjusted EPS $2.51 and revenues $53.6B, signaling stronger margins.
- Company raised full-year adjusted EPS floor to >$4.80 and revenue to $193.5-$197.5B.
- Management said about $0.50 of Q2 adjusted EPS reflected non-recurring settlement items.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Centene Corporation (CNC) reported second-quarter results on July 28, 2026, prompting the company to raise its full-year profit outlook after improved medical-cost control and stronger revenue across Medicare, Medicaid, and Marketplace. The results signal a step-up in near-term earnings momentum.
Quarter Results and Drivers
For the quarter ended June 30, 2026, Centene reported GAAP diluted earnings per share (EPS) of $2.19 and adjusted diluted EPS of $2.51, with total revenues of $53.6 billion and net income attributable to Centene of $1.1 billion. Premium and service revenues rose 4.0% to $44.4 billion from a year earlier. Operating cash flow reached $3.6 billion. The selling, general, and administrative (SG&A) expense ratio was 7.0%, with adjusted SG&A at 6.9%.
The health benefits ratio (HBR), also known as the medical loss ratio, improved to 89.6%, reflecting better pricing and tighter medical-cost management. Medicare HBR was 89.5%, driven by outperformance in Medicare Advantage and the prescription-drug-plan business. Medicaid HBR stood at 93.9%, consistent with expectations and ongoing medical cost trend management. Centene highlighted premium yield and prescription-drug-plan membership growth, Marketplace and Medicaid rate increases to address medical trends, Marketplace risk-adjustment revenue transfers for the 2025 and 2026 benefit years, and state-directed payments. The commercial segment posted a health benefits ratio of 79.2%, marking a significant year-over-year improvement in profitability.
Raised 2026 Guidance
Centene raised its full-year 2026 guidance, setting an adjusted diluted EPS floor above $4.80, a GAAP diluted EPS floor above $3.11, and total revenue between $193.5 billion and $197.5 billion. Management said about $0.50 of the quarter’s adjusted EPS reflected non-recurring settlement items. It also expects Medicaid membership to decline 8.0% to 9.0% in 2026.
Through the first half of 2026, Centene reported $103.5 billion in revenue and $2.6 billion in profit, compared with $95.4 billion and $1.1 billion in the same period of 2025. Stronger medical-cost metrics and operating cash flow allowed the company to raise earnings and revenue targets, even as management noted the impact of one-time items and declining Medicaid membership on margin sustainability.
